Clinical trials: Inflammatory Bowel Disease 1
Crohn Disease
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's…
- Trial name
- mRE-EEN (NCT06216899)
- Testing
- Whole-food based smoothie, Formula
- Where
- 3 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Seattle Children's Hospital
Inflammatory Bowel Diseases, Blau Syndrome
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single…
- Conditions
- Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT06206811
- Testing
- OD-07656
- Where
- Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Odyssey Therapeutics, Inc.
Inflammatory Bowel Diseases
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
This study evaluates 2 therapeutic strategies (increase infliximab dose or add an immunosuppressant) in patients with inflammatory bowel disease in loss of response to infliximab.
- Trial name
- STAMP (NCT03370601)
- Testing
- Infliximab, Mercaptopurine, Azathioprine
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Lille
Crohn's Disease, Prenatal Exposure
Pregnancy Exposure Registry for Tysabri®
The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last…
- Conditions
- Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
- Trial name
- NCT00472992
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Biogen
Rheumatoid Arthritis, Ankylosing Spondylitis
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis
- Trial name
- TRANSREG (NCT01988506)
- Testing
- Interleukin 2
- Where
- 11 sites in France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ulcerative Colitis, Ulcerative Colitis Chronic
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
- Trial name
- SHINE-ON (NCT04844606)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Austria and 14 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Crohn Disease
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].
- Trial name
- NCT00552344
- Testing
- Cimzia
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 403 people
- Sponsor
- UCB BIOSCIENCES GmbH
Crohn Disease
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
With this prospective, randomized, multicentre, parallel group pragmatic non-inferiority trial, the investigators will evaluate if endoscopy-driven introduction of biological therapy is not leading to more postoperative…
- Trial name
- SOPRANO-CD (NCT05169593)
- Testing
- Biological Drug
- Where
- 28 sites in Belgium, Italy
- Volunteers
- 292 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Crohn's Disease
Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease
The purpose of this study is to determine whether the addition of vitamin D to standard corticosteroids improves onset of remission in active Crohn's Disease, a form of Inflammatory Bowel Disease (IBD).
- Trial name
- IBDVit1 (NCT00672763)
- Testing
- Colecalciferol D3 (Vigantol Oil), Medium chain triglycerides
- Where
- 2 sites in United Kingdom
- Sponsor
- Imperial College London
Crohn's Disease (CD)
Microbial Community Characteristics in Intestinal Mucosal Tissue of Patients With CD
The characteristics of the intestinal microbiota in Crohn's disease and their relationship with disease pathogenesis have not yet been fully elucidated.
- Trial name
- NCT06895772
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shandong University
Rectal Cancer, Colon Cancer
Perfusion Assessment in Laparoscopic Left Anterior Resection
The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic…
- Conditions
- Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp
- Trial name
- PILLAR II (NCT01560377)
- Testing
- PINPOINT Endoscopic Fluorescence Imaging System
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Crohn's Disease
VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease
The primary objective of the study is to compare the efficacy of the probiotic VSL#3 versus placebo, in addition to standard maintenance drugs, in maintaining remission in Crohn's disease (CD).
- Trial name
- NCT00114465
- Testing
- VSL#3
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Orphan Australia
Crohn's Disease
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
- Trial name
- GEMINI III (NCT01224171)
- Testing
- vedolizumab
- Where
- 41 sites in United States, Canada
- Volunteers
- 416 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn's Disease
Treatment With Infliximab in a Medical Setting (Study P05587)
This is an open-label, interventional study where a subset of participants will be randomized to one of two treatment-optimization strategies.
- Trial name
- OPTIMIST (NCT00752622)
- Testing
- Infliximab 5 mg/kg, Infliximab 5 mg/kg every 6 weeks, Infliximab 7 mg/kg every 8 weeks
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis
The study is proposed as a 2-year single site, open-label clinical trial of enteral nutrition or the specific carbohydrate diet in patients with active CD or UC.
- Trial name
- NCT02412553
- Testing
- Specific carbohydrate diet, Elemental diet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Inflamatory Bowel Disease, Crohn Disease (CD)
Non-nutritive Sweeteners in Inflammatory Bowel Disease
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with IBD, compared to healthy…
- Trial name
- NCT07769437
- Testing
- Sucralose (non-nutritive sweetener)
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Crohn Disease
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years.
- Trial name
- POP-REMIND (NCT03458195)
- Testing
- bio-banking collection
- Where
- 17 sites in Belgium, France
- Volunteers
- 575 people
- Sponsor
- Saint-Louis Hospital, Paris, France
Inflammatory Bowel Disease
An Epidemiological Study of the Incidence of Inflammatory Bowel Disease in Spain
This is a prospective, observational, multicenter, population-based incidence cohort study which will enroll cases of IBD (CD, UC, or indeterminate colitis) diagnosed in adults over 1 year in Spain.
- Trial name
- INCIDENCIA (NCT02686892)
- Where
- 16 sites in Spain
- Volunteers
- 4,000 people
- Sponsor
- Javier P. Gisbert
Crohn Disease (CD), Crohns Disease
Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC).
- Conditions
- Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
- Trial name
- NCT07059130
- Testing
- Mirikizumab
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Rubix LS
Crohn Disease, Plaque Psoriasis
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
ROLL'YN-UST is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided…
- Trial name
- ROLL'YN-UST (NCT06997055)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.